Stockchase Opinions

Robert Floyd Vasogin VAS-T BUY Jan 07, 2005

Have been building up their balance sheet to complete their final trials. Are now approaching a critical time. Feels the company can start to look better from here.
$6.450

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

DON'T BUY
Prefers companies with consistent earnings. Too speculative for them.
DON'T BUY
Have no earnings and won’t for the next 3 years. Model price is $1.50.
DON'T BUY
They are risk model on bile tax turned negative a couple of months ago so they sold their holdings. Well-run and has an interesting product. They are in the process of being listed in the US. Wait for some strength in that sector.
HOLD
Have signed on with a bigger company and now have to wait for the revenues and earnings to kick in. Easy money has been made.
BUY
Interesting technology.
TOP PICK
Top Short Doesn't feel they have a lot of R&D to show. Have a lot of cash on the books.
PAST TOP PICK

(Top Short Sept 8/04. Sold in low $5's so he's ahead about 19%.)

DON'T BUY
This one is past the point of no return. Speculative.
DON'T BUY
When a biotech finds the right thing, the stock can jump like crazy. This company just had a 1 for 10 reverse split. 90% of companies that do a reverse split are still down one year later.